Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response

References

• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol Baltim Md. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Chedid MF. Nonalcoholic steatohepatitis: the second leading indication for liver transplantation in the USA. Dig Dis Sci. 2017 Oct 1;62(10):2621–2622.
   PubMed Web of Science ®Google Scholar
• Ray K. NAFLD-the next global epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):621.
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017 Aug;67(2):302–309.
   PubMed Web of Science ®Google Scholar
• Cancer today [Internet]. [cited 2018 Mar 27]. Available from: http://gco.iarc.fr/today/home
   Google Scholar
• Nolan JP. Endotoxin, reticuloendothelial function, and liver injury. Hepatology. 1981 Sep 1;1(5):458–465.
   PubMed Web of Science ®Google Scholar
• Teixeira TFS, Collado MC, Ferreira CLLF, et al. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr Res. 2012 Sep 1;32(9):637–647.
   PubMed Web of Science ®Google Scholar
• Das UN. Is obesity an inflammatory condition? Nutrition. 2001 Nov 1;17(11):953–966.
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003 Dec;112(12):1796–1808.
   PubMed Web of Science ®Google Scholar
• Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006 Jun;116(6):1494–1505.
   PubMed Web of Science ®Google Scholar
• Brun P, Castagliuolo I, Leo VD, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol-Gastrointest Liver Physiol. 2007 Feb 1;292(2):G518–25.
   PubMed Web of Science ®Google Scholar
• Kim K-A, Gu W, Lee I-A, et al. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PloS One. 2012;7(10):e47713.
   PubMed Web of Science ®Google Scholar
• Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G256–265.
   PubMed Web of Science ®Google Scholar
• Lu Y-C, Yeh W-C, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008 May 1;42(2):145–151.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol WJG. 2014 Nov 14;20(42):15539–15548.
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Mellemkjaer L, Jepsen P, et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol. 2003 Apr;36(4):356–359.
   PubMed Web of Science ®Google Scholar
• Kawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol. 2009 Dec 1;44(12):1190.
   PubMed Web of Science ®Google Scholar
• Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014 Jan;60(1):110–117.
   PubMed Web of Science ®Google Scholar
• Hirsova P, Ibrahim SH, Gores GJ, et al. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res. 2016;57(10):1758–1770.
   PubMed Web of Science ®Google Scholar
• Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. Int J Mol Sci [Internet]. 2016 Sep 20 [cited 2018 Apr 17];17(9). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037841/
   PubMed Web of Science ®Google Scholar
• Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM Int J Med. 2010 Feb;103(2):71–83.
   PubMed Web of Science ®Google Scholar
• Magee N, Zou A, Zhang Y. Pathogenesis of nonalcoholic steatohepatitis: interactions between liver parenchymal and nonparenchymal cells. BioMed Res Int [Internet]. 2016 [cited 2018 Apr 17];2016:1–11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086374/
   Google Scholar
• Dapito DH, Mencin A, Gwak G-Y, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012 Apr 17;21(4):504–516.
   PubMed Web of Science ®Google Scholar
• Chassaing B, Etienne‐Mesmin L Gewirtz AT. Microbiota‐liver axis in hepatic disease. Hepatology. 2013 Nov 15;59(1):328–339.
   PubMedGoogle Scholar
• Ríos-Covián D, Ruas-Madiedo P, Margolles A, et al. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol [Internet]. 2016 [cited 2018 Apr 1];7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756104/
   PubMed Web of Science ®Google Scholar
• Canani RB, Costanzo MD, Leone L, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011 Mar 28;17(12):1519–1528.
   PubMed Web of Science ®Google Scholar
• Sheng L, Jena PK, Hu Y, et al. Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation. J Pathol. 2017 Dec;243(4):431–441.
   PubMed Web of Science ®Google Scholar
• Sommer F, Bäckhed F. The gut microbiota — masters of host development and physiology. Nat Rev Microbiol. 2013 Apr;11(4):227–238.
   PubMed Web of Science ®Google Scholar
• Ley RE, Bäckhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA. 2005 Aug 2;102(31):11070–11075.
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006 Dec 21;444(7122):1027–1031.
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009 Jan 22;457(7228):480–484.
   PubMed Web of Science ®Google Scholar
• Zhu A, Chen J, Wu P, et al. Cationic polystyrene resolves nonalcoholic steatohepatitis, obesity, and metabolic disorders by promoting eubiosis of gut microbiota and decreasing endotoxemia. Diabetes. 2017;66(8):2137–2143.
   PubMed Web of Science ®Google Scholar
• Koliada A, Syzenko G, Moseiko V, et al. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol [Internet]. 2017 May 22 [cited 2018 Aug 17];17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440985/
   PubMed Web of Science ®Google Scholar
• Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010 Jan 1;18(1):190–195.
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatol Baltim Md. 2013 Feb;57(2):601–609.
   PubMed Web of Science ®Google Scholar
• Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011 Jul 1;94(1):58–65.
   PubMed Web of Science ®Google Scholar
• Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes. 2008 Nov;32(11):1720–1724.
   PubMed Web of Science ®Google Scholar
• Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015 Feb;91(2):1–9.
   PubMed Web of Science ®Google Scholar
• Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006 Dec;444(7122):1022–1023.
   PubMed Web of Science ®Google Scholar
• Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatol Baltim Md. 2016 Mar;63(3):764–775.
   PubMed Web of Science ®Google Scholar
• Del Chierico F, Nobili V, Vernocchi P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatol Baltim Md. 2017;65(2):451–464.
   PubMed Web of Science ®Google Scholar
• Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013 Jul 1;11(7):868–875.e3.
   PubMed Web of Science ®Google Scholar
• Wong VW-S, Tse C-H, Lam TT-Y, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis – a longitudinal study. PLoS ONE [Internet]. 2013 Apr 25 [cited 2018 Aug 17];8(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636208/
   Web of Science ®Google Scholar
• Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology [Internet]. [cited 2018 Aug 23]. Available from: https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.30036
   Google Scholar
• Grąt M, Wronka KM, Krasnodębski M, et al. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transplant Proc. 2016 Jun;48(5):1687–1691.
   PubMed Web of Science ®Google Scholar
• Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013 Oct;14(10):996–1006.
   PubMed Web of Science ®Google Scholar
• Elsegood CL, Tirnitz-Parker JE, Olynyk JK, et al. Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. Clin Transl Immunol. 2017 Nov;6(11):e161.
   PubMedGoogle Scholar
• Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016 Mar 10;531(7593):253–257.
   PubMed Web of Science ®Google Scholar
• Greyer M, Whitney PG, Stock AT, et al. T cell help amplifies innate signals in CD8(+) DCs for optimal CD8(+) T cell priming. Cell Rep. 2016 Jan 26;14(3):586–597.
   PubMed Web of Science ®Google Scholar
• Shi F, Shi M, Zeng Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011 Feb 15;128(4):887–896.
   PubMed Web of Science ®Google Scholar
• Kalathil S, Lugade AA, Miller A, et al. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013 Apr 15;73(8):2435–2444.
   PubMed Web of Science ®Google Scholar
• Fu S, Zhang N, Yopp AC, et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2004 Oct;4(10):1614–1627.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11;369(2):134–144.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015 Jan 22;372(4):311–319.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455–2465.
   PubMed Web of Science ®Google Scholar
• Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther. 2016 Aug 12;9:5023–5039.
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal. Nat Immunol. 2009 Nov;10(11):1185–1192.
   PubMed Web of Science ®Google Scholar
• Pentcheva-Hoang T, Egen JG, Wojnoonski K, et al. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004 Sep;21(3):401–413.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet Lond Engl. 2017 Jun 24;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013 Jul 1;59(1):81–88.
   PubMed Web of Science ®Google Scholar
• Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: patho-physiological mechanisms and therapeutic perspectives. Eur J Cancer Oxf Engl 1990. 2017;87:101–112.
   PubMed Web of Science ®Google Scholar
• Kudo M. Immuno-oncology in hepatocellular carcinoma: 2017 update. Oncology. 2017;93(Suppl 1):147–159.
   PubMed Web of Science ®Google Scholar
• Molloy MJ, Bouladoux N, Belkaid Y. Intestinal microbiota: shaping local and systemic immune responses. Semin Immunol. 2012 Feb;24(1):58–66.
   PubMed Web of Science ®Google Scholar
• Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004 Mar 12;303(5664):1662–1665.
   PubMed Web of Science ®Google Scholar
• Mazmanian SK, Liu CH, Tzianabos AO, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005 Jul 15;122(1):107–118.
   PubMed Web of Science ®Google Scholar
• Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011 Jan 21;331(6015):337–341.
   PubMed Web of Science ®Google Scholar
• Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013 Dec 19;504(7480):451–455.
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014 Mar 27;157(1):121–141.
   PubMed Web of Science ®Google Scholar
• Blaschitz C, Raffatellu M. Th17 cytokines and the gut mucosal barrier. J Clin Immunol. 2010 Mar;30(2):196–203.
   PubMed Web of Science ®Google Scholar
• Gide TN, Wilmott JS, Scolyer RA, et al. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2018 Mar 15;24(6):1260–1270.
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017 Apr 15;23(8):1920–1928.
   Google Scholar
• Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015 Nov 27;350(6264):1079–1084.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27;350(6264):1084–1089.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91–97.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 05;359(6371):97–103.
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 05;359(6371):104–108.
   PubMed Web of Science ®Google Scholar
• Donor Recruitment for Fecal Microbiota Transplantation | Inflammatory Bowel Diseases | Oxford Academic [Internet]. [cited 2018 Feb 19]. Available from: https://academic.oup.com/ibdjournal/article/21/7/1600/4604260
   Google Scholar
• Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis. 2015 Jan;2(1):ofv004.
   PubMed Web of Science ®Google Scholar
• Staley C, Hamilton MJ, Vaughn BP, et al. Successful resolution of recurrent clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol. 2017 Jun;112(6):940–947.
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent clostridium difficile infection. J Clin Gastroenterol. 2011 Nov;45(Suppl):S159–167.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017 Oct 1;11(10):1180–1199.
   PubMed Web of Science ®Google Scholar
• Kang D-W, Adams JB, Gregory AC, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017 23;5(1):10.
   PubMed Web of Science ®Google Scholar
• Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood. 2016 20;128(16):2083–2088.
   PubMed Web of Science ®Google Scholar
• Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913–916.e7.
   PubMed Web of Science ®Google Scholar
• Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017 May 8;7(1):1529.
   PubMedGoogle Scholar
• Home - ClinicalTrials.gov [Internet]. [cited 2018 Apr 10]. Available from: https://clinicaltrials.gov/ct2/home
   Google Scholar
• Li J, Sung CYJ, Lee N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci USA. 2016 Mar 1;113(9):E1306–15.
   PubMed Web of Science ®Google Scholar
• Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005 Jul;100(7):1539–1546.
   PubMed Web of Science ®Google Scholar
• Gupta P, Andrew H, Kirschner BS, et al. Is lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000 Oct;31(4):453–457.
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004 Nov;53(11):1617–1623.
   PubMed Web of Science ®Google Scholar
• Lee T-Y, Wu J-C, Yu S-H, et al. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer. 2017 01;141(7):1307–1314.
   PubMed Web of Science ®Google Scholar
• Hamilton MJ, Weingarden AR, Unno T, et al. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013 Jan 1;4(2):125–135.
   PubMedGoogle Scholar
• Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. J Hepatol. 2001 Sep 1;35(3):421–430.
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016 Jan 4;36(S1):124–129.
   PubMedGoogle Scholar
• Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017 Mar;66(3):545–551.
   PubMed Web of Science ®Google Scholar